BRCA1 and triple-negative breast carcinoma: The mechanisms of action of eribulin and platinum drugs are different, and previous studies have not compared the effects of eribulin and platinum drugs as salvage therapy in recurrent metastatic triple-negative breast cancer, with or without BRCA1/2 gene mutations.